Dravix™

Dravix™

Therapeutic Segment: Anti-Fibrinolytic Agent

Generic Name: Tranexamic acid

Indication:

For the treatment of:

Hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis may occur in the following conditions:

  • Prostatectomy and bladder surgery
  • Menorrhagia
  • Epistaxis
  • Conisation of the cervix
  • Management of dental extraction in patients with coagulopathies
  • Ulcerative colitis
  • Hematuria
  • Gastrointestinal hemorrhage.

General fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery:

  • in obstetrical complications such as abruptio placentae and post-partum hemorrhage
  • in leukemia and liver diseases and in connection with thrombolytic therapy with streptokinase

Hereditary angioneurotic oedema:

  • For the reduction of peri- and post-operative blood loss and the need for blood transfusion in
    adult patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.
  • For the reduction of peri- and post-operative blood loss and the need for blood transfusion in
    pediatric patients undergoing cardiac surgery.

Available as:

Capsules
  • 500MG
Injectables
  • 500mg/5ml